Why the study?
Does high sodium intake reduce the antiproteinuric response to ACEI/ARB drugs in kidney transplant recipients?
Does high sodium intake reduce the antiproteinuric response to ACEI/ARB drugs in kidney transplant recipients?
High salt intake blunts the antiproteinuric efficacy of ACE inhibitors and ARBs in kidney transplant recipients, suggesting dietary sodium restriction is important in this population.
High sodium intake was associated with blunted antiproteinuric response to ACEI/ARB post-transplant; leaves open whether restriction improves graft outcomes.
Background Post-transplant proteinuria is associated with lower graft and patient survival. Renin–angiotensin–aldosterone system blockers are used to reduce proteinuria and improve renal outcome. Although it is known that a high salt intake blunts the antiproteinuric effect of ACEI and ARB drugs in non-transplant patients, this effect has not been studied in kidney transplant recipients. Objective To analyse the relationship between sodium intake and the antiproteinuric effect of ACEI/ARB drugs in kidney transplant recipients. Methods We selected 103 kidney transplant recipients receiving ACEI/ARB drugs for more than 6 months due to proteinuria >1 g/day. Proteinuria was analysed at baseline and at 6 months after starting ACEI/ARB treatment. Salt intake was estimated by urinary sodium to creatinine ratio (uNa/Cr). Results Proteinuria fell to less than 1 g/day in 46 patients (44.7%). High uNa/Cr was associated with a smaller proteinuria decrease ( r = −0.251, p = 0.011). The percentage of proteinuria reduction was significantly lower in patients in the highest uNa/Cr tertile [63.9% (IQR 47.1%), 60.1% (IQR 55.4%), 38.9% (IQR 85.5%), p = 0.047]. High uNa/Cr independently relates (OR 2.406 per 100 mEq/g, 95% CI: 1.008–5.745, p = 0.048) to an antiproteinuric response <50% after renin–angiotensin–aldosterone system blockade. Conclusions A high salt intake results in a smaller proteinuria decrease in kidney transplant recipients with proteinuria treated with ACEI/ARB drugs.
No takes yet. Share an insight, caveat, or question.
Monfá et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: